In another large retrospective study of 5300 patients with CMO secondary to CRVO and treated with intravitreal anti-VEGF therapies, BCVA gain at 1 year was 7.1 letters (95% CI 6.31 to 7.95) from a baseline BCVA of 39.5 letters [16]. The gene discussed is VEGFA; the disease is chronic recurrent multifocal osteomyelitis.